Hexvix

Hexvix is a prescription‑only diagnostic agent whose active ingredient is hexaminolevulinate. It is supplied as a solution for intravesical instillation, with the specific strength not disclosed in the product label. Marketed in the European Union, Hexvix is classified as a photosensitizer used during cystoscopic procedures to help identify malignant lesions of the bladder. The formulation is applied directly into the bladder under controlled conditions clinical setting.

Hexvix is indicated for the detection of non‑muscle invasive bladder cancer during cystoscopic examination, helping clinicians identify malignant urothelial tissue that may be missed with standard white‑light imaging.

- Detection of carcinoma in situ (CIS) of the bladder. - Identification of papillary urothelial tumors (Ta, T1). - Adjunct to white‑light cystoscopy for improved lesion visualization. - Guidance for targeted biopsy or resection of suspicious areas. - Assessment of treatment response after intravesical therapy. - Documentation of disease extent for surgical planning. - Differentiation between inflammatory changes and malignant lesions.

Adverse reactions reported with Hexvix are generally related to the intravesical administration and the photosensitizing properties of hexaminolevulinate.

Common: - Bladder discomfort or urgency during or after instillation. - Transient hematuria or mild urinary irritation. - Mild erythema of the urethral or bladder mucosa. - Dysuria or burning sensation during urination. - Mild abdominal cramping that resolves within a few hours after the procedure. - Flank pain or renal colic. - Nausea associated with the procedure.

Serious: - Severe allergic reaction including anaphylaxis. - Persistent urinary retention requiring catheterization. - Prolonged photosensitivity leading to skin irritation after exposure to strong light. - Bladder ulceration or necrosis. - Systemic photosensitivity causing severe skin reactions. - Acute urinary tract infection secondary to catheterization.

Before using Hexvix, clinicians should consider several precautionary measures to minimize risks and ensure optimal diagnostic performance.

- Verify that the patient has no known hypersensitivity to hexaminolevulinate or related compounds. - Ensure proper bladder emptying and catheter placement prior to instillation. - Avoid use in patients with active urinary tract infection unless treated. - Limit exposure to bright light after the procedure to reduce photosensitivity reactions. - Document any prior bladder surgeries or radiation therapy that may affect mucosal integrity. - Assess renal function if large volumes are used, as impaired clearance may increase exposure.

Hexvix may interact with other agents or conditions that influence photosensitivity or bladder physiology.

Avoid: - Concurrent use of systemic photosensitizing drugs (e.g., porfimer sodium, aminolevulinic acid). - Administration of topical or oral photosensitizers within 48 hours of the procedure. - Use of strong UV light sources in the operating room during or immediately after instillation.

Use with caution: - Use of anticoagulants or antiplatelet agents, which may increase risk of hematuria. - Concurrent intravesical chemotherapy agents, requiring spacing to avoid additive irritation. - Patients with severe renal impairment, where drug clearance may be altered. - Presence of active bladder inflammation, which may enhance mucosal uptake and increase fluorescence background.